Adobe Flash Player is required to view this feature. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Original Article Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma James Larkin, M.D., Ph.D., Vanna Chiarion-Sileni, M.D., Rene Gonzalez, M.D., Jean Jacques Grob, M.D., C. Lance Cowey, M.D., Christopher D.

Lao, M.D., M.P.H., Dirk Schadendorf, M.D., Reinhard Dummer, M.D., Michael Smylie, M.D., Piotr Rutkowski, M.D., Ph.D., Pier F. Ferrucci, M.D., Andrew Hill, M.D., John Wagstaff, M.D., Matteo S. Carlino, M.D., John B. Haanen, M.D., Michele Maio, M.D., Ph.D., Ivan Marquez-Rodas, M.D., Ph.D., Grant A. McArthur, M.D., Paolo A.

Read or Download The Turning Tide (eBook) online f. Read online or Download The Turning Tide (Full PDF ebook with essay, research paper) by Bill Baldwin. Product Details. ISBN-13: 788; Publisher: Booklocker.com, Inc. Publication date:; Pages: 372; Sales rank: 567,982; Product dimensions:. The Turning Tide. By Bill Baldwin. Science Fiction Space Opera with unusual alternate-history twist. (PDF, ePub, and Kindle). Around him, the Second Great war continues apace, even as his beleaguered old Empire begins to turn the tide of conflict toward ultimate victory over The League of Dark Stars.

Ascierto, M.D., Georgina V. Long, M.D., Margaret K. Callahan, M.D., Ph.D., Michael A. Postow, M.D., Kenneth Grossmann, M.D., Mario Sznol, M.D., Brigitte Dreno, M.D., Lars Bastholt, M.D., Arvin Yang, M.D., Ph.D., Linda M. Rollin, Ph.D., Christine Horak, Ph.D., F. Stephen Hodi, M.D., and Jedd D.

Wolchok, M.D., Ph.D. N Engl J Med 2015; 373:23-34 DOI: 10.1056/NEJMoa1504030. Results The median progression-free survival was 11.5 months (95% confidence interval [CI], 8.9 to 16.7) with nivolumab plus ipilimumab, as compared with 2.9 months (95% CI, 2.8 to 3.4) with ipilimumab (hazard ratio for death or disease progression, 0.42; 99. Accel Dfi Thruster Software. 5% CI, 0.31 to 0.57; P. Figure 1 Progression-free Survival. Panel A shows the Kaplan–Meier curves for progression-free survival in the intention-to-treat population.

Patients were followed for a minimum of 9 months. The median progression-free survival was 6. Stackridge Something For The Weekend Rar Files. 9 months (95% CI, 4.3 to 9.5) in the nivolumab group, 11.5 months (95% CI, 8.9 to 16.7) in the nivolumab-plus-ipilimumab group, and 2.9 months (95% CI, 2.8 to 3.4) in the ipilimumab group. Significantly longer progression-free survival was observed in the nivolumab-plus-ipilimumab group than in the ipilimumab group (hazard ratio for death or disease progression, 0.42; 99.5% CI, 0.31 to 0.57; P. Figure 2 Tumor-Burden Change in Target Lesions.